Hemorrheological indices, catecholamines, neuropeptide Y and serotonin in patients with essential hypertension

Blood Pressure

Volumn 6, Issue 4, 1997, Pages 203-208

  Berent, Hanna ^b   Kuczyńska, Krystyna ^b   Kochmański, Marek ^a   Wocial, Bozena ^b   Łapiński, Mariusz ^b   Lewandowski, Jacek ^b   Januszewicz, Andrzej ^b   Ignatowska Świtalska, Hanna ^b   Januszewicz, Włodzimierz ^b  

^a CENTRAL CLINICAL HOSPITAL   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Hypertension; Platelets; Rheology; Sympatho adrenal system

Indexed keywords

CATECHOLAMINE; NEUROPEPTIDE Y; SEROTONIN;

ADULT; ARTICLE; BLOOD RHEOLOGY; CATECHOLAMINE BLOOD LEVEL; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA VISCOSITY; PRIORITY JOURNAL; SEROTONIN BLOOD LEVEL; SEX DIFFERENCE;

EID: 0030850932     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059709062070     Document Type: Article

References (34)

1. Chabanel A, Chien S. Blood viscosity as a factor in human hypertension. In: Laragh JH, Brenner BM (eds). Hypertension: pathophysiology, diagnosis, and management, ed 2. New York, Raven Press, 1995: 365-76.
2. Lip GYH, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8: 693-702.
3. Leschke M, Vogt M, Motz W, et al. Blood rheology as a contributing factor in reduced coronary reserve in systemic hypertension. Am J Cardiol 1990; 65: 566-96.
4. Vanhoutte PM. Serotonin and the cardiovascular system. New York: Raven Press, 1985.
5. Floras JS, Haro K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens 1993; 11: 647-55.
6. Mancia G, Grassi G, Parati G, et al. Evaluating sympathetic activity in human hypertension. J Hypertens 1993; 11(Suppl. 5): S13-S19.
7. De Clerck F: Blood platelets in human essential hypertension. Agents and Actions 1986; 18 (5/6): 563-80.
8. Wocial B, Ignatowska-Switalska H, Pruszczyk P, et al. Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Pressure 1995; 4: 143-7.
9. Wocial B, Ignatowska-Switalska H, Pruszczyk P, et al. Plasma neuropeptide Y and alpha-adrenoceptor interactions in patients with essential hypertension. Mat Med Pol 1994; 26: 127-31.
10. Chien S: Blood rheology in hypertension and cardiovascular disease. Cardiovasc Med 1977; 2: 356-60.
11. Kannel WB. The clinical heterogeneity of hypertension. Am J Hypertens 1991; 4: 283-7.
12. Letcher RL, Chien S, Pickering TG, et al. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Am J Med 1981; 70: 1195-202.
13. Dintenfass L. Blood viscosity, hyperviscosity and hyperviscosaemia. Lancaster, Pennsylvania: MTP Press, 1985.
14. Lowe GDO. Blood rheology in arterial disease. Clin Sci 1986; 71: 137-46.
15. Fogari R, Zoppi A, Marasi G, et al. Associations between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men. J Cardiovasc Risk 1994; 1: 341-5.
16. Koenig W, Sund M, Ernst E, et al. Is increased plasma viscosity a risk factor for high blood pressure? Angiology 1989; 40: 153-63.
17. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
18. Dintenfass L. Rheology of blood in diagnostic and preventive medicine. Boston and London: Butterworths, 1976.
19. Folsom A. Fibrinogen and cardiovascular risk in the atherosclerosis risk communities CARIC Study. In: Ernst E, Koenig W, Low GOO, Meade TW (eds): Fibrinogen, a new cardiovascular risk factor. Oxford, 1992.
20. Ernst E, Koenig W. Plasma fibrinogen: an independent cardiovascular risk factor. J Intern Med 1990; 227: 365-72.
21. Smith EB, Keeng G, Grant A, et al. Fate of fibrinogen in human arterial intima. Atherosclerosis 1990; 10: 263-75.
22. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984: 311: 501-5.
23. Fowkes FG, Pell JP, Donnan PT, et al. Sex differences in susceptibility to etiologic factors for peripheral atherosclerosis. Importance of plasma fibrinogen and blood viscosity. Arterioscler Thromb 1994; 14(6): 862-8.
24. Pretolani E, Salvi P, Montagui L, et al: The blood rheological and microcirculatory changes in the hypertensive patient. Cardiologia 1991: 36, (Suppl. 1): 355-63.
25. Vaya A, Marinez M, Garcia J, et al. Hemorheological alterations in mild essential hypertension. Thromb Res 1992; 66: 223-9.
26. Di Perri T: Rheological factors in circulatory disorders. Angiology 1979; 30: 480-486.
27. Dormandy JA, Yates CJP, Berent GA. Clinical relevance of blood viscosity and red cell deformability including newer therapeutic aspects. Angiology 1981; 32: 236-42.
28. 2+ concentration in essential hypertension. Hypertension 1992; 19(2): 167-74.
29. + transport abnormalities. Hypertension 1990; 15: 234-6.
30. Longhini E, Agosti R, Cherubini P, et al. Haemorrheology in hypertension. Clin Haemorrheol 1986; 6: 567-76.
31. Lundberg JM, Hemsen A, et al. Neuropeptide Y receptors in pig spleen: binding characteristics, reduction of cyclic AMP formation and calcium antagonists inhibition of vasoconstriction. Eur J Pharmacol 1988; 145: 21-9.
32. Westlind-Danielsson A, Andell S. Neuropeptide Y and peptide YY inhibit cyclase activity in the rat stratium. Acta Physiol Scand 1988; 14: 263-70.
33. Wahlestedt C, Haknson R, Vaz CA. et al. Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro. Am J Physiol 1990; 258: R736-42.
34. Żukowska-Grójec Z, Pruszczyk P, Colton C, et al. Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 1993; 14(2): 263-8.